Medipattern™ Corporation Signs Enterprise Wide B-CAD-FOR-LIFE(TM) Contract With Zwanger-Pesiri Radiology

TORONTO, ONTARIO--(Marketwire - April 30, 2009) - Attention: Business/Financial Editors

The Medipattern Corporation (“Medipattern”)(TSX VENTURE: MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, today announces the signing of an Enterprise Wide B-CAD-FOR-LIFE™ managed service contract with Zwanger-Pesiri Radiology, Long Island’s largest private medical imaging practice. From its eight locations with over 400 employees Zwanger-Pesiri provides state of the art services to the communities of Nassau and Suffolk Counties in New York. B-CAD® Computer Aided Detection (CAD) for breast ultrasound imaging will be implemented throughout the multi-site practice. B-CAD-FOR-LIFE provides all of the separate components that are required to install, train, use and maintain B-CAD under one monthly service fee.

“Zwanger-Pesiri is dedicated to patient care, compassion and empathy creating a relaxing, soothing environment focused on patient comfort,” said Steven Mendelsohn, MD medical director and co-owner of Zwanger-Pesiri Radiology. “With over 35 sonographers and over 35 radiologists serving eight facilities, we believe that one of the keys to our success is flexibility, communication and standardized protocols to ensure consistent quality of care through the entire organization. All of our staff can operate in any office allowing us to book appointments conveniently for our patients. Workflow is a core strategy in implementing our plans. B-CAD fits perfectly into this philosophy. B-CAD will enable us to have comprehensive standardized breast ultrasound reports that conform to the American College of Radiology (ACR) BI-RADS® ultrasound lexicon. We have learned that the use of standardized protocols increases throughput while maintaining a high standard of medical excellence,” concluded Dr. Mendelsohn.

“Currently, our sonographers are filling in a hand written worksheet which they scan in and store digitally in our RIS. This takes up a lot of costly storage space on our systems and takes valuable sonographer time to scan these documents into our system. B-CAD will save us storage space and time. B-CAD allows for the creation of comprehensive digital worksheets that can be shared throughout our enterprise and can be read by any of our radiologists regardless of where they are located,” commented Matt Dewey, Chief Information Officer of Zwanger-Pesiri. “One of the difficulties we deal with everyday is variety of hand writing and phrasing that is unique to each sonographer which needs to be reviewed when radiologists interpret the case. B-CAD will eliminate this nuisance and provide a consistent look and feel that will accommodate our needs through customized templates and adherence to the ACR standards.”

Zwanger-Pesiri was founded in 1953 with the purpose of providing referring physicians and patients on Long Island with modern medical diagnostics. The practice was the first in the area to offer specialized imaging with a 3 Tesla MRI, first with 128 slice CT following on in the tradition of providing leading edge, innovative medicine to better care for the community.

“In this economic environment, we want to provide our customers an affordable solution that enables them to access the latest ultrasound B-CAD innovations,” added Mr. Collins, CEO of The Medipattern Corporation. “B-CAD-FOR-LIFE clearly fulfills this need. Customers can use B-CAD and gain all the benefits of the system for three months before the first monthly fee is due. We are very pleased to be working with Zwanger Pesiri as they are considered by many to be thought leaders in the industry. We would also like to congratulate our reseller Amy Eriksen of Physicians Consultant Medical Sales of New York for facilitating this transaction.”

2009 Upcoming Events:

- BIC (Breast Imaging Conference), September 4-5, 2009 in Nashville, TN partnered with GE

- RSNA (Radiological Society of North America), November 29 to December 3, 2009, Chicago, IL

About The Medipattern Corporation:

Medipattern® (TSX VENTURE: MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company’s website at: www.medipattern.com.

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern’s performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern’s current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as “anticipates,’' “believes,’' “estimates,’' “expects,’' “plans,’' “intends,’' “potential’’, and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company’s corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.